Forest Laboratories, Inc.'s (FRX) Fibromyalgia Phase 3 Study Doesn't Meet Goal
Forest Laboratories, Inc.'s (FRX) Fibromyalgia Phase 3 Study Doesn't Meet Goal
BioSpace - NEW YORK, Sept. 28 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and Cypress Bioscience, Inc. development of milnacipran as a treatment for fibromyalgia (FMS). Although the results did not development of milnacipran as a treatment for fibromyalgia. In an analysis using
/C O R R E C T I O N -- Forest Laboratories, Inc.; Cypress Biosciences, Inc./
PR Newswire via Yahoo! - III Study for Milnacipran as a Treatment for Fibromyalgia, issued earlier today by Forest Laboratories of milnacipran as a treatment for fibromyalgia (FMS). Although the results did
Technorati Tags:
fibromylagia treatment